Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM2023-05: GTB-3650 TriKE for High Risk MDS and R/R AML
NCT06594445Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of GTB-3650 in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (7 arms), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started Nov 2024; status: recruiting.
02
Drugs
GTB-3650
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06594445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06594445.